Weekly Recap: Bayer AG Q2 sales growth and Roundup settlement opt-out cap

Bayer AG (XETR:BAYN) reported modest sales growth and mixed earnings, laid out 2026 targets and net-debt goals, and strengthened its balance sheet via a $3B Apollo equity injection and $5B bond issue while advancing a Roundup settlement, U.S. reorganization under Ruveon LLC and talks of a breakup.

Previous Week Recap

• BAYN Q2 Sales Up, Core EPS Down: Bayer (BAYN) Q2 sales €10.87–10.9B (+2% YoY); EBITDA before specials rose; core EPS down ~16.7%; H1 sales €24.3B (+3%); confirms 2026 sales €44.7–46.7B, core EPS €4.20–4.70, net debt €29–30B. 3 sources
• Bayer Roundup U.S. Settlement Framework: Bayer AG (BAYN) set a U.S. Roundup settlement framework: needs under 650 plaintiff opt-outs to proceed; may cut up to $400M from fund if opt-outs exceed threshold; opt-out vetting included. Reuters
• Supreme Court Win Eases Risk; Apollo Investment Increases: Bayer (BAYN) saw litigation risk ease after a Supreme Court win. Apollo invested €3B equity and Bayer issued $5B in bonds, strengthening its capital structure and balance sheet. Quartr
• U.S. Roundup Operations Reorganized Under Ruveon: Bayer AG (BAYN) said it’s reorganizing U.S. Roundup operations under Ruveon LLC. Restructuring may include additional divestitures or spin-offs as part of broader U.S. reorganization efforts. Reuters
• Bayer Breakup Talk: Split, IPOs Possible: Bayer AG (BAYN) breakup discussed: split into agriculture, pharma and consumer health; possible partial Monsanto IPO. High debt and cash outflows limit options; pharma must be strengthened first. Dow Jones Newswires
• Low Rhine Levels Not Disrupting Operations: Bayer (BAYN) says low Rhine water levels have so far not disrupted operations or supply chains; company reports no current operational impact from reduced river levels. Reuters